Physician profile
Larry Baros
NPI 1992841860
$919.15
in general payments reported to CMS, 2019-2025
10 companies · $15.54 in 2025
The $15.54 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2020: $285 · 2021: $255 · 2022: $71.20 · 2023: $46.45 · 2024: $73.17 · 2025: $15.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $135.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $451.74 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $211.65 | 2019-2021 | |
| Allergan, INC. | $53.22 | 2020 | |
| Azurity Pharmaceuticals, INC. | $46.80 | 2023-2024 | Edarbi, Edarbi |
| Astrazeneca Pharmaceuticals LP | $44.42 | 2024 | Breztri |
| Esperion Therapeutics, INC. | $37.80 | 2021 | |
| Abbvie INC. | $29.58 | 2021-2022 | |
| Amgen INC. | $15.54 | 2025 | Krystexxa |
| Idorsia Pharmaceuticals US INC | $14.96 | 2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.44 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Baros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.